Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Propels 'Lung Leadership' Plans

Reimagines Operating Models As Q4 Sales Hit By COVID-19

Executive Summary

Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.

You may also be interested in...



COVID-19 Demand Gives Lupin Optimism On Albuterol

Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.

Gilead Licensing Deal Expands Remdesivir Access, Capacity

Gilead’s voluntary licensing of remdesivir to five companies while temporarily charging no royalty and allowing them pricing latitude for 127 developing countries not only expands market access but tilts the pricing debate in Gilead’s favor. It also brings significant potential add-on manufacturing capacity.

Gilead Licenses Remdesivir To Five Firms

Gilead has announced a raft of licensing agreements with five generics firms to manufacture potential COVID-19 treatment remdesivir for distribution in 127 countries.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC066183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel